Quantcast
Last updated on April 17, 2014 at 17:30 EDT

Latest Rhinitis Stories

2008-08-05 12:01:07

Meda has submitted the registration application to the FDA for azelastine nasal spray in the new formulation with extra strength. The application seeks approval to treat symptoms of seasonal allergic rhinitis and perennial allergic rhinitis. The new formulation is patent pending. Six Phase III studies evaluating efficacy and safety and long term safety have been conducted involving about 1,600 patients treated with azelastine extra strength. The higher strength has been shown to offer...

2008-08-04 03:00:32

Regulatory News: Meda AB (STO:MEDAA): The registration application for azelastine nasal spray in the new formulation with Extra Strength has been submitted to the US Food and Drug Administration (FDA), seeking approval to treat symptoms of Seasonal Allergic Rhinitis and Perennial Allergic Rhinitis. The new formulation is patent pending. Six phase III studies evaluating efficacy and safety and a long term safety have been conducted involving about 1,600 patients treated with...

2008-07-31 21:00:36

There is a link between alcohol consumption and increased risk of perennial allergic rhinitis -- runny nose -- Danish researchers said. The study of 5,870 young adult women, published in the Clinical and Experimental Allergy, found the risk increased 3 percent for every additional alcoholic drink per week. In contrast, lead author Dr. Janne Tolstrup of the National Institute of Public Health in Denmark, did not observe any increase in risk of seasonal allergic rhinitis according to...

2008-07-30 09:01:27

SANTA ROSA, Calif., July 30 /PRNewswire/ -- While summer is the time of year people like to spend most of their day outside, summer allergens keep many sinus sufferers from enjoying activities such as barbequing, hanging out at the pool and spending time in the park, to name a few. In fact, a new survey of more than 1,000 consumers shows that one-third of sinus sufferers say they miss or cut short social outings or business engagements because of their symptoms. With ragweed season right...

2008-07-18 12:01:14

Schering-Plough has announced that Schering-Plough KK, the company's country operation in Japan, has received marketing approval for Nasonex nasal spray 50mcg for the treatment of allergic rhinitis in adult patients. Schering-Plough's Nasonex is an intranasal steroid that significantly improves nasal allergy symptoms when taken once each day. Nasonex is said to be the first intranasal steroid to be approved in Japan for once-daily administration. Nasonex is currently approved in over 100...

2008-07-17 12:01:18

KENILWORTH, N.J., July 17 /PRNewswire-FirstCall/ -- Schering-Plough Corporation today announced that Schering-Plough K.K., the company's country operation in Japan, has received marketing approval for NASONEX(R) (mometasone furoate monohydrate) Nasal Spray 50mcg* for the treatment of allergic rhinitis in adult patients.(1) NASONEX is an intranasal steroid that significantly improves nasal allergy symptoms when taken once each day. NASONEX is the first intranasal steroid to be approved in...

2008-07-01 00:14:24

By Madhavi Rajadhyaksha MUMBAI: If you've been blaming your allergic cough, running nose and itchy skin on flowering trees or neighbourhood pets, it's time to do a rethink. Insects, particularly mosquitoes, cockroaches and dust mites, are to blame for nearly 50% of the allergies in India. And food - especially peanuts, chocolates and legumes - is the other big culprit. This is what a Mumbai allergy specialist found after he set out to map the "desi" allergy index. "Since we are a...

2008-06-27 03:02:32

Greer has completed enrollment for its pivotal Phase III clinical trial designed to study the efficacy of sublingual-oral immunotherapy as a treatment for adults with allergic rhinoconjunctivitis caused by short ragweed pollen. Between March and June 2008, 556 patients were screened for the randomized, double-blind, placebo-controlled trial, of which 430 were enrolled. The participants will be observed at 31 clinical sites across the country. The trial will last approximately seven...

2008-06-26 12:03:21

Greer, a leading developer and provider of allergy immunotherapy products and services, has completed enrollment for its pivotal Phase III clinical trial designed to study the efficacy of sublingual-oral immunotherapy (SLIT) as a treatment for adults with allergic rhinoconjunctivitis caused by short ragweed pollen. It is estimated that 30 million Americans are allergic to short ragweed pollen, making it one of the most common allergens. Between March and June, 556 patients were screened...

2008-06-25 06:03:22

Morria Biopharmaceuticals has initiated a Phase II equivalent study of MRX-4, in a nasal aerosol formulation, in 105 patients suffering from allergic rhinitis. The two-arm, randomized, multi-dose, double-blind, placebo-controlled study includes Rhinocort as the steroid comparator arm. The study is expected to be completed by the end of third quarter 2008. The study is designed to evaluate the safety, tolerability, and efficacy of intranasal MRX-4 in allergic rhinitis (AR) patients outside...